eligibility_summary
Inclusion: path-confirmed unresectable advanced solid tumor, ≥1 prior systemic therapy with progression, measurable lesion (RECIST 1.1), ECOG 0-1, life expectancy ≥3 months, adequate organ function, contraception: WCBP two methods during +7 months, males condoms during +4 months. Exclusion: prior TF-targeted or topo I ADCs, CNS metastases, ocular surface/cicatrizing disease, persistent toxicities, bleeding disorders, significant cardiac disease, ILD/pneumonitis, other malignancy except allowed.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: ADCE-T02 (AMT-754), an intravenously administered antibody-drug conjugate (ADC). Mechanism: a monoclonal antibody targets Tissue Factor (TF, CD142/F3) on tumor cells, after binding and internalization, the ADC releases a cytotoxic payload inside the cell to induce cancer cell death. Design: first-in-human phase 1, single-agent dose escalation with expansion in advanced solid tumors. Targets/pathways: TF-expressing malignant cells and tumor-associated vasculature, entry via the TF/extrinsic coagulation pathway. Note: prior TF-directed agents or ADCs with topo I payloads are excluded.